Xarelto vs Trelegy Ellipta
Side-by-side drug price comparison from Medicare Part D data
Verdict
Xarelto costs 16% less per claim than Trelegy Ellipta ($321.00 vs $380.00). Xarelto has a generic alternative available. Total Medicare spending: Xarelto at $5.0B vs Trelegy Ellipta at $2.9B.
| Metric | Xarelto | Trelegy Ellipta |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $321* | $380 |
| Total Medicare Spending Total Medicare Part D spending on this drug | $5.0B | $2.9B |
| Total Claims | 15,680,000 | 7,560,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | -1.2%* | 19.8% |
| Generic Available | Yes | No |
| Condition | Blood Clots | Asthma/COPD |
| Total Beneficiaries | 1,920,000 | 865,000 |
Xarelto costs 16% less per claim than Trelegy Ellipta ($321.00 vs $380.00). Xarelto has a generic alternative available. Total Medicare spending: Xarelto at $5.0B vs Trelegy Ellipta at $2.9B.
Explore More
Comparing Xarelto and Trelegy Ellipta on U.S. Medicare prescription-drug pricing requires lining up the underlying CMS Medicare Part D Drug Spending data data side by side. The table above runs the comparison on the canonical fields; the narrative below identifies the factor or factors that drive the most meaningful difference between the two.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.